Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute inferior mycardial infarction (defined as an episode of chest pain lasting \>30 minutes and electrocardiographic evidence of 1 mm or greater ST elevation in inferior leads) within the past 72 hours.~* Invasive hemodynamic evidence of hemodynamically-significant RV dysfunction, defined as the presence of all the following: systemic venous congestion (mean RA pressure \> 10mmHg), the ratio of RA/PCW pressure 0.75 or greater, a low cardiac output as determined by Fick or Thermodilution (TD) technique (cardiac index \< 2.5 l/min/m2), systolic systemic arterial blood pressure of 90mmHg or less or requiring vasopressor or mechanical support to maintain systolic pressure \> 90mmHg. Patients with a PCWP of 14mmHg or less should receive intravascular volume repletion until their PCWP is \> 14mmHg.~* Coronary angiography revealing either an occlusion of the RCA proximal to any RV marginal branch or evidence of diminished flow to RV marginal branches of the RCA.~* If patient undergoes coronary revascularization, there must be evidence of unsuccessful right ventricular reperfusion (lack of restoration of TIMI grade III flow in the distal RCA and \> 1mm RV marginal branches) or evidence of hemodynamically significant RVI must persist for greater than 1 hour after successful revascularization.~* Age 18 years or greater~Exclusion Criteria:~* PCW 25mmHg or greater or mechanical complications of myocardial infarction requiring surgical correction.~* Severe LV systolic dysfunction as determined by the principal investigator. Unprotected left main coronary stenosis \> 50%.~* Pulmonary infiltrates consistent with pulonary edema on chest X-ray (if chest X-ray is clinically indicated).~* Evidence of shock-related end-organ damage, including creatinine 3.0 or greater, metabolic acidosis (pH 7.1 or less) and not corrected by 100 ml NaHCO3 (1mEq/ml), disseminated intravascular coagulation, or clinical evidence of diffuse brain injury.~* Previous history of severe pericardial, congenital, or valvular heart disease.~* Refractory hemodynamically significant arrhythmia.~* Presence of pneumonia, adult respiratory distress syndrome, or sepsis.~* Prior history of pulmonary disease requiring chronic oxygen therapy.~* Pregnancy~* Use of investigational drugs or device within the 30 days prior to enrollment to the study.~* Uncontrolled active bleeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): inhaled nitric oxide at 40 or 80ppm
- 2 (Type: PLACEBO_COMPARATOR): inhaled nitrogen at either 40 or 80ppm

Based on this trial design, predict the completion outcome and termination type (if applicable).